News & Updates
Filter by Specialty:
Cathepsin S levels predict survival in NSTE-ACS patients
Circulating cathepsin S (CTSS) is significantly associated with long-term mortality and may be used to enhance risk stratification of patients with non–ST-segment elevation acute coronary syndrome (NSTE-ACS) over the Global Registry of Acute Coronary Events (GRACE) risk score, suggests a study.
Cathepsin S levels predict survival in NSTE-ACS patients
09 Sep 2022Slow progress to heart failure, death seen in patients with d-TGA after atrial switch
Most adults with d-loop transposition of the great arteries (d-TGA) after atrial switch operation exhibit slow progression to end-stage heart failure or death, according to a recent study.
Slow progress to heart failure, death seen in patients with d-TGA after atrial switch
09 Sep 2022Nine metabolic biomarkers can detect gastric cancer
Gastric cancer (GC) patients show an altered metabolic profile as compared with healthy individuals, a recent China study has found. A biomarker panel monitoring for nine metabolites can facilitate timely detection of GC.
Nine metabolic biomarkers can detect gastric cancer
09 Sep 2022CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.
CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
09 Sep 2022Insulin glargine, degludec yield comparable effects on glycaemic control
In patients with of type 2 diabetes (T2D), glargine 300 U/mL (Gla-300) and degludec 100 U/mL (Deg-100) deliver similar improvements in glycaemic control, without increasing weight and hypoglycaemic events over 6 months of treatment, according to data from the retrospective RESTORE-2 NAIVE study.
Insulin glargine, degludec yield comparable effects on glycaemic control
09 Sep 2022Semaglutide lowers stroke risk in type 2 diabetes with high CV risk
A post hoc analysis of the SUSTAIN 6 and PIONEER 6 trials has found that semaglutide reduces incidence of any stroke in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk vs placebo.